A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA
Mad in America
AUGUST 14, 2024
By late 2023, the general public perception was of two strong phase 3 trials that demonstrated the treatment’s efficacy in healing those with PTSD. But when subjected to the FDA advisory committee’s scrutiny, the supposed strengths of these trials fell apart.
127 
Let's personalize your content